See more : Fusion Pharmaceuticals Inc. (FUSN) Income Statement Analysis – Financial Results
Complete financial analysis of Capricor Therapeutics, Inc. (CAPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Capricor Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Om Infra Limited (OMINFRAL.NS) Income Statement Analysis – Financial Results
- Enermax Technology Corporation (8093.TWO) Income Statement Analysis – Financial Results
- Goldseek Resources Inc. (GSKKF) Income Statement Analysis – Financial Results
- Alpha Partners Technology Merger Corp. (APTMW) Income Statement Analysis – Financial Results
- India Power Corporation Limited (DPSCLTD.NS) Income Statement Analysis – Financial Results
Capricor Therapeutics, Inc. (CAPR)
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.18M | 2.55M | 244.90K | 310.25K | 1.01M | 1.67M | 1.37M | 3.19M | 3.78M | 4.79M | 503.23K | 195.50K | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 694.87K | 245.70K | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.11M | 1.85M | -799.00 | -8.15M | -4.14M | -10.40M | -9.40M | -12.85M | -9.98M | -3.00M | -4.69M | -2.44M | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 95.75% | 72.74% | -0.33% | -2,625.87% | -411.61% | -621.98% | -687.46% | -402.87% | -264.33% | -62.69% | -932.76% | -1,247.43% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 36.45M | 21.82M | 13.57M | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 1.02M | 4.14M | 4.08M | 4.47M | 9.48M | 5.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.43K | 0.00 |
| SG&A | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.22K | 10.43K | 0.00 |
| Other Expenses | 0.00 | 190.58K | 548.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 545.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00 | 26.09K | 200.00 |
| Operating Expenses | 48.19M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Cost & Expenses | 49.26M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Interest Income | 1.73M | 0.00 | 57.46K | 32.94K | 94.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23K | 6.01K | 20.38K | 47.19K | 332.72K | 287.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 398.81K | 344.67K | 248.63K | 200.51K | 58.13K | 0.00 | 0.00 | 0.00 | 0.00 | 137.00 | 1.09M | 950.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.07M | 694.87K | 245.70K | 143.89K | 171.96K | 157.65K | 144.17K | 134.64K | 110.87K | 41.90K | 26.92K | 6.26K | 7.51K | 12.93K | 159.59K | 113.29K | 26.98K | 0.00 | 0.00 | -900.00 | 0.00 | -2.19K | 83.00 | 200.00 | 200.00 |
| EBITDA | -23.01M | -29.16M | -20.69M | -13.55M | -7.56M | -15.17M | -12.72M | -18.33M | -12.50M | -5.97M | -6.88M | -1.89M | -4.88M | -6.02M | -7.71M | -13.02M | -9.50M | -2.50M | -18.86K | -19.88K | -16.16K | -19.97K | -22.22K | -36.32K | 200.00 |
| EBITDA Ratio | -91.39% | -1,184.21% | -8,700.01% | -4,423.18% | -778.68% | -917.04% | -940.79% | -532.16% | -334.00% | -124.85% | -1,366.36% | -1,244.33% | -361.76% | 0.00% | 0.00% | 0.00% | -9,342.68% | 0.00% | 0.00% | 0.00% | -739.79% | -173.90% | 0.00% | 0.00% | 0.00% |
| Operating Income | -24.08M | -29.70M | -20.94M | -13.69M | -7.73M | -15.33M | -12.86M | -16.98M | -12.61M | -6.02M | -6.90M | -2.44M | -4.90M | -6.29M | -7.88M | -13.40M | -9.50M | -60.40K | -18.86K | -18.98K | -16.16K | -17.78K | -22.30K | -36.52K | -200.00 |
| Operating Income Ratio | -95.63% | -1,165.10% | -8,549.86% | -4,412.56% | -769.52% | -917.04% | -940.79% | -532.16% | -334.00% | -125.72% | -1,371.71% | -1,248.15% | -361.70% | 0.00% | 0.00% | 0.00% | -9,369.29% | 0.00% | 0.00% | 0.00% | -739.79% | -154.82% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.79M | 677.85K | 915.92K | 32.94K | 92.07K | 135.99K | 15.29M | -1.83M | -245.51K | -198.61K | -1.99M | 207.00K | 14.39K | 262.06K | 11.41K | 268.39K | -802.34K | -950.00 | 0.00 | 900.00 | 16.16K | 2.19K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -22.29M | -29.02M | -20.02M | -13.66M | -7.64M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88B | -6.03B | -7.87B | -13.13B | -10.30M | -61.35K | 0.00 | -18.08K | 0.00 | -15.59K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -88.52% | -1,138.50% | -8,175.86% | -4,401.94% | -760.36% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360,633.89% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | 0.00% | -135.73% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -677.85 | -613.41K | -176.83K | -264.03K | 135.99K | 254.63K | 218.95K | 137.76K | 200.51K | 58.13K | 0.00 | -14.39K | -262.06K | -11.41K | -268.39K | 1.09M | 0.00 | 18.86K | 0.00 | 16.16K | 0.00 | 0.00 | 0.00 | 200.00 |
| Net Income | -22.29M | -29.02M | -19.41M | -13.48M | -7.38M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88M | -6.03M | -7.87M | -13.13M | -10.30M | -61.35K | -18.86K | -18.08K | -16.16K | -15.59K | -22.30K | -36.52K | -200.00 |
| Net Income Ratio | -88.52% | -1,138.48% | -7,925.38% | -4,344.95% | -734.09% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360.63% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | -739.79% | -135.73% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| EPS Diluted | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 0.90 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| Weighted Avg Shares Out | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.32M | 1.86M | 1.59M | 1.17M | 1.05M | 994.52K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
| Weighted Avg Shares Out (Dil) | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.68M | 1.86M | 1.59M | 1.17M | 1.05M | 994.53K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that...
Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch
There is an ongoing phase 3 study, known as HOPE-3, deploying the use of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy; Interim analysis expected Q4 of 2023. A Type-B FDA meeting was held between the company and...
Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2023 Earnings Call Transcript August 7, 2023 4:20 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good afternoon, ladies and gentlemen...
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; On Track to Complete Enrollment and Report Interim Analysis in Fourth...
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial...
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D.
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment...
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
-John Hopkins School of Medicine Clinical Director Joins Capricor's Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience-
Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Safety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference Safety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference
Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen, this...
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
-Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET- -Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET-
Source: https://incomestatements.info
Category: Stock Reports